

The Sixteenth Annual Conference

ABSTRACTS OF INVITED PRESENTATIONS

1 Eradication of Disease through Vaccination: The 35th Anniversary of the Last Case of Smallpox

D.A. Henderson, MD, MPH

Johns Hopkins Bloomberg School of Public Health

Center for Biosecurity of University of Pittsburgh Medical Center

Baltimore, MD

Objective: Understand the factors that were responsible for the eradication of smallpox and the relevance of the most salient, current, and contemplated initiatives for the eradication of other infectious diseases.

Abstract: In January 1967, the World Health Organization (WHO) with its member countries commenced a 10 year program of global smallpox eradication intended to interrupt transmission of the virus by December 31, 1976. It missed that target, but only by 10 months and 26 days. However, a year later, two additional cases occurred, in September 1978, in Birmingham, England, as a result of a laboratory mishap. No other cases have subsequently been identified. Thus, this year, the world celebrates the 35th year without a smallpox case. The program of smallpox eradication was launched under less than auspicious conditions. WHO's only eradication program-for malaria-was in its 13th year but it was foundering. A proposal to undertake smallpox eradication was opposed by many delegates and by the Director General on the grounds that the concept of disease eradication was not tenable and the costs were too great. Some five years later, malaria eradication was 'ropped as a goal.

Meanwhile, as smallpox eradication was being certified, many former smallpox staff, both national and international, began or joined national "Expanded Programs of Immunization" which had been launched during the course of the smallpox eradication program. The vaccines initially included measles and polio, along with DTP (diphtheria, tetanus, pertussis). Gradually, other vaccines were selectively added; in some countries numbering ten or more. Meanwhile, a belief in eradication as a feasible public health program objective lay dormant for nearly a decade until, in 1986, WHO embarked upon a Guinea worm disease eradication program and, in 1988, a polio eradication program. They were targeted to accomplish their objectives by 2000. Both have made extraordinary progress but both are struggling with endemic foci in areas locked in civil conflict. Efforts to launch a global measles eradication effort have been endorsed and successful in two WHO regions but have yet to be accepted elsewhere, including Europe. Meanwhile, eradication enthusiasts with a special interest in a particular disease have been emerging with increasing frequency. Individual programs are now identified that are intended to eradicate trachoma, leprosy, lymphatic filariasis, and sleeping sickness (African trypanosomiasis). Several of these, in theory, could perhaps be eradicated, as could measles, but there is a substantial gap between theories of the possible and the practical realities of execution, as those engaged in the polio and Guinea worm eradication programs will testify. The virtues of launching a special eradication campaign, with the attendant publicity and pleas for funds, need to be weighed against possible repercussions of credibility and disillusionment associated with failure – as malariologists will agree.

References:

1. Fenner F, Henderson DA, Arita I, et al. Lessons and Benefits, Chapter 31 in *Smallpox and its Eradication*. Geneva: World Health Organization, 1988. p.1345-1370. Available: <https://extranet.who.int/iris/restricted/bitstream/10665/39485/1/9241561106.pdf>. Accessed March 6, 2013.
2. Maurice J. New WHO plan targets the demise of sleeping sickness. *Lancet*. 2013 Jan 5; 381(9860):13-4.

birth 1946 to

Notes

MILA letters

EXPERIMENTS - "Eradication of Disease through Vaccines - 30th Anniversary of ~~the~~ the last wave"
Determination

35 yrs.

~~7.25 1987~~

1974 ~~1975~~ EPI

8.25 1981

1992 My address to (MILA) (problems)

~~5.25 1977~~

explosive epidemics - 50% of 70 health care. What would 70 years bring?

NE India - 40% of

Most deaths in 70 yrs

~~Case of polio in 1914~~

6000-8000 cases/month

world-wide resurgence

Polio as head of recommendation - tip of the hat to Mike's home

14 infected, 4%

to subcontinent stuff

to fight polio AOS Variant.

20000-50000 cases/month

to complete to EA not conditions

to Polio

1976 re. 20000

15.2 Polio

VP-97

Baker 62

159 x 10⁶ ppl

March - July 20000 - 50000 cases/month

15.16 Personnel

June 25

(only 7 in Oct 73)

May 1994

L

ARM Form - vaccination

- ① Growth on calves (excellent production → calves.)
 - ② Enriched - calves had dose to dose
 - ③ 864 - people brought to vaccine center
 - ④ liquid vaccine - vacuum pump + capillary tubes + glass needles. Vaccine struck the skin / could be kept refrigerated for long periods at -10°C.
- Single dose or up to 25 doses.
Take calves of 20% or less. 4' 2 to 4 injections.

⑤ Air-dried vaccine - Jenner sent vaccine on threads or between glass slides.
 ↳ FRANCIS (Carnot & Fraquiere) 1909 Vaccine for tuberculous focus - dried over H₂SO₄ - successful in > 75% of vaccines after storage for 12 months but heavily contaminated and was not easy to use for commercial production.

10 x 10⁶ doses sent annually to French colonies 1920-1940 produced at Paris Vaccine Institute
 FREEZE-DRYING DEVICE (had sublimated water from liquid to gas) Packed in tubes under a vacuum
 1948 WHO Study Group - 1st meeting report of French work.
 1950 Fred Lynn - coordinator in Americas. Asked Mich. State H^B labs to develop this commercially.
 Lister Institute + shelf-dried

1953 full production could begin
 1958 Int'l. standards adopted → 1965 (Revised)
 Bacterial count originally up to 1000 /ml.; seed lot system
 1959 Minimum filter of 5 x 10⁷ f.p.u. adopted internationally
 filtered in eggs rather than (re-bats); Δ stability still. Kept by U.S. until 1971!
 @ then need of eggs.

No international quality control -
 VACCINE VS R 5241

Est. med 300 x 10⁶ DONATIONS INTO WHO 25-50 x 10⁶ / yr.
 Testing slow & primitive only 59 of 72 reported
 producers - 11 dif. manuf. of vaccine drying equip.
 At least 17 different vaccine virus strains in use. Most produced in 100+ dose containers
 Quality control - 31/52 meet WHO primary standards; Δ stability satisfactory < 20%

1967 < 10% of vaccine in use met accepted international standards. Need to IMPROVE QUALITY CONTROL
 Samples submitted by ¹²⁴⁹ techs. involving vaccination supply plan to Program -

22/35 batches did not meet potency req.;

1968
 Majority of vaccine producers

UNICEF + Edwards F. D.

REQUIRED all vaccine provided to countries actively engaged in WHO in S.E. had to meet international standards.

Goals of SPX

① Assurance - Most important - adeq. supply of fully potent vaccine that meets intl. standards

② SURVEILLANCE -

Enumeration and characterization of cases.

③ On-going interactive research program field + laboratory

④ MANAGEMENT

⑤ FLEXIBILITY in strategy, in research.

e.g.

INFORM

INTER